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Relaxin family peptide (RXFPs) 1‐4 receptors modulate the activity of cyclic adeno-
sine monophosphate (cAMP) to produce a range of physiological functions. RXFP1
and RXFP2 increase cAMP via Gαs, whereas RXFP3 and RXFP4 inhibit cAMP via
Gαi/o. RXFP1 also shows a delayed increase in cAMP downstream of Gαi3. In this
study we have assessed whether the bioluminescence resonance energy transfer
(BRET)‐based biosensor CAMYEL (cAMP sensor using YFP‐Epac‐Rluc), which allows
real‐time measurement of cAMP activity in live cells, will aid in understanding
ligand‐ and cell‐specific RXFP signaling. CAMYEL detected concentration‐dependent
changes in cAMP activity at RXFP1‐4 in recombinant cell lines, using a variety of
ligands with potencies comparable to those seen in conventional cAMP assays. We
used RXFP2 and RXFP3 antagonists to demonstrate that CAMYEL detects dynamic
changes in cAMP by reversing cAMP activation or inhibition respectively, with real‐
time addition of antagonist after agonist stimulation. To demonstrate the utility of
CAMYEL to detect cAMP activation in native cells expressing low levels of RXFP
receptor, we cloned CAMYEL into a lentiviral vector and transduced THP‐1 cells,
which express low levels of RXFP1. THP‐1 CAMYEL cells demonstrated robust
cAMP activation in response to relaxin. However, the CAMYEL assay was unable to
detect the Gαi3‐mediated phase of RXFP1 cAMP activation in PTX‐treated THP‐1
cells or HEK293A cells with knockout of Gαs. Our data demonstrate that cytoplas-
mically‐expressed CAMYEL efficiently detects real‐time cAMP activation by Gαs or
inhibition by Gαi/o but may not detect cAMP generated in specific intracellular com-
partments such as that generated by Gαi3 upon RXFP1 activation.
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Abbreviations: AC, adenylate cyclase; BRET, bioluminescence resonance energy transfer; cAMP, cyclic adenosine monophosphate; CAMYEL, cAMP sensor using YFP-Epac-Rluc; DAPI, 4′,6-
diamidino-2-phenylindole; Epac, exchange protein activated by cAMP; FACS, fluorescence-activated cell sorting; FRET, Förster/fluorescence resonance energy transfer; GPCR, G protein-
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luciferase; RXFP, relaxin family peptide receptor; TAMRA, 5-carboxytetramethylrhodamine; YFP, yellow fluorescent protein.
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1 | INTRODUCTION
G protein‐coupled receptors (GPCRs) are one of the largest families
of proteins in the human genome, and regulate most aspects of
human physiology. GPCRs initiate a variety of intracellular signaling
cascades in response to a diverse range of ligands, by coupling to
effectors including G proteins and β‐arrestins. Biased signaling is a
key research topic in GPCR drug development, referring to the abil-
ity of different ligands to favor coupling of the receptor to particular
effectors, leading to activation of only a subset of the receptor's sig-
naling pathways.1 A related concept is system bias, whereby differ-
ent cell types can show preferential coupling to particular
downstream signaling pathways.2
The relaxin family of peptides target GPCRs to produce a broad
array of physiological functions across a range of tissues including
the reproductive system, cardiovascular system, connective tissue,
gastrointestinal tract, and brain (reviewed in [3,4]). In humans, the
relaxin family of peptides contains seven members, including H1
relaxin, H2 relaxin, H3 relaxin, insulin‐like peptide (INSL) 3, INSL4,
INSL5, and INSL6. The actions of relaxin peptides are mediated by
relaxin family peptide receptors (RXFPs) 1‐4.5 H2 relaxin and INSL3
are the cognate ligands for RXFP16 and RXFP2,7 and relaxin‐3 and
INSL5 are the cognate ligands for RXFP38 and RXFP4,9 respectively.
The receptors for INSL4 and INSL6 have not been identified.
One of the primary second messengers involved in RXFP recep-
tor signaling is 3′,5′‐cyclic adenosine monophosphate (cAMP). Effec-
tors of cAMP include protein kinase A (PKA), exchange protein
directly activated by cAMP (Epac), and cyclic nucleotide‐gated ion
channels. Activation of a Gαs‐coupled GPCR leads to synthesis of
cAMP via adenylate cyclases (ACs), whereas activation of a Gαi/o‐
coupled receptor leads to inhibition of ACs. RXFP1 and RXFP2 cou-
ple to Gαs to increase cAMP activity, which is negatively modulated
by GαoB.6,10 Unusually, RXFP1 also couples to Gαi3 to increase
cAMP downstream of Gβγ, PI3K, PKC‐ζ, and AC5 in a number of cell
types.10-13 In contrast, RXFP3 and RXFP4 couple to Gαi/o proteins
to inhibit the production of cAMP.14,15 However, patterns of cAMP
activity also depend on the cell type being stimulated. For example,
fibroblasts that natively express RXFP1 show little or no increases in
cAMP activity when stimulated with an RXFP1 agonist.16-18
Traditional assays for detecting cAMP activity do not easily mea-
sure the temporal aspects of signaling, but measuring the kinetics of
signaling aids accurate detection of biased signaling.19 A real‐time
assay for cAMP activity that can be used in native cells will there-
fore be valuable for understanding ligand‐ and cell‐specific effects of
RXFP signaling, as well as for screening novel ligands acting at these
receptors. Fortunately, there is a real‐time, genetically‐encoded bio-
luminescence resonance energy transfer (BRET)‐based biosensor for
cAMP activity. BRET is the transfer of energy from an excited luci-
ferase donor to a fluorophore acceptor, when they are in close prox-
imity. CAMYEL (cAMP sensor using YFP‐Epac‐Rluc) is a unimolecular
BRET‐based biosensor for cAMP activity, consisting of truncated and
catalytically inactive human Epac1 sandwiched between Rluc (the
donor) and a monomeric and circularly permuted form of the YFP
citrine (the acceptor).20 When cAMP is not present, Epac adopts a
“closed” conformation, where the donor and acceptor are in close
proximity, producing a BRET signal. When cAMP binds to Epac, the
donor and acceptor move farther apart, reducing BRET. These
changes in BRET can be monitored in real time in live cells at 37°C.
In this study, we demonstrated the use and versatility of
CAMYEL for detecting real‐time cAMP activity at RXFP1‐4 and
developed and validated a CAMYEL lentiviral vector for the trans-
duction of native cells expressing RXFP1. However, we were unable
to detect the delayed phase of cAMP activity at RXFP1 mediated by
Gαi3 suggesting that the CAMYEL sensor, when expressed in the
cytoplasm, may not detect cAMP generated in specific intracellular
compartments.
2 | MATERIALS AND METHODS
2.1 | Reagents and materials
DMEM, DMEM/F12, RPMI 1640, trypsin/EDTA, L‐glutamine, peni-
cillin/streptomycin, DPBS, Gateway enzymes, Lipofectamine 2000
(Invitrogen); FBS (Scientifix); BSA, forskolin, HEPES, PTX (Sigma‐
Aldrich); Viafect (Promega); coelenterazine h (Nanolight); Cul-
turPlate96 (PerkinElmer); RXFP1 agonists: H2 relaxin and the small
molecule ML29021; RXFP2 agonists: INSL3 and H2 relaxin; antago-
nist: INSL3 B‐chain dimer22; RXFP3 agonists: analogue 2 (H3 relaxin
analogue)23, peptide 5 (single‐chain H3 relaxin analogue)24, R3/I59;
antagonist: R3 B1‐22R25; RXFP4 agonists: INSL5 and analogue 13
(INSL5 analogue).26
2.2 | Synthesis of H2 relaxin labeled with TAMRA
Individual A‐ and B‐chains of H2 relaxin with appropriate regioselec-
tive S‐protection were synthesised using a CEM Liberty peptide syn-
thesiser.27 The amine‐reactive fluorophore 5(6)‐TAMRA succinimidyl
ester (Anaspec) was attached to the N‐terminus of the A‐chain
sequence using a manual coupling procedure. Following purification
of the crude peptides stepwise formation of the three disulfide
bonds was conducted as described.27 The final TAMRA‐labelled H2
relaxin was subjected to characterization by RP‐HPLC and MALDI‐
TOF mass spectrometry to confirm its high purity and correct molec-
ular mass (m/z calculated [M+Na]+, 6415.456, found 6419.70).
2.3 | Cell culture
Cell culture media was supplemented with 10% fetal bovine serum,
1% penicillin/streptomycin, and 1% L‐glutamine (complete media).
Human embryonic kidney (HEK) 293T and 293A cells were grown in
complete Dulbecco's modified Eagle medium (DMEM), Chinese ham-
ster ovary (CHO‐K1) cells in complete DMEM/F12, and THP‐1 cells
in complete RPMI 1640 medium (ATCC modification). All cells were
cultured at 37°C with 5% CO2. Experiments were conducted in
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HEK293T cells stably expressing RXFP1 (HEK‐RXFP1), RXFP2
(HEK‐RXFP2), or RXFP3 (HEK‐RXFP3), THP‐1 cells endogenously
expressing RXFP1, CHO‐K1 (FlpIn) cells stably expressing RXFP3
(CHO‐RXFP3),28 and CHO‐K1 cells stably expressing RXFP4 (CHO‐
RXFP4).29 Experiments were also conducted in HEK293A parental
cells and HEK293A cells that do not express the Gαs subunit
(ΔGαs).30
2.4 | Real‐time BRET assays for cAMP activity in
live cells
Adherent cells were seeded on six‐well plates and were transfected
the following day with CAMYEL in the pcDNA3.1/His vector,20 using
Lipofectamine 2000 (HEK) or Viafect (CHO), according to the manu-
facturers’ instructions. HEK293A cells were also transfected with
RXFP1 or the Gαs subunit in the pcDNA3.1/Zeo vector. The next
day, cells were detached resuspended in complete media containing
25 mmol L−1 HEPES but no phenol red, reseeded into opaque white
96‐well CulturPlates and grown overnight. Non‐adherent THP‐1 cells
stably expressing CAMYEL (see below) were plated directly onto
CulturPlates at 80 000 (PTX assays) or 120 000 cells per well in
complete RPMI 1640 containing 25 mmol L−1 HEPES but no phenol
red. For all Gαi/o inhibition assays, PTX was added to wells at a final
concentration of 100 ng mL−1 at least 16 hours before ligand
stimulations. Peptides were diluted in complete phenol red free
media and ML290 was diluted in DMSO. Media for cells stimu-
lated with ML290 was also replaced with 0.5% FBS media before
the assay.
Light emissions from the luciferase (Rluc) and YFP (citrine) were
measured using a POLARstar Omega plate reader (BMG Labtech) at
37°C. Cells were pre‐incubated with the luciferase substrate coelen-
terazine h (Nanolight) at a final concentration of 5 μmol L−1 for 5
minutes to establish a baseline, followed by addition of vehicle or
ligand. For Gαi/o assays, indicated concentrations of forskolin were
added after a pre‐incubation of at least four minutes with agonist.
Emissions were measured simultaneously at the wavelength win-
dows 475/30 nm (Rluc) and 535/30 nm (citrine). Ligand‐induced
BRET ratio was calculated by subtracting the ratio of citrine to Rluc
emissions for vehicle‐treated wells from the same ratio for ligand‐
treated cells.31 For CAMYEL, a decrease in ligand‐induced BRET
ratio corresponds to an increase in cAMP, so negative values were
converted to positive values and vice versa.
2.5 | Analysis of BRET data
cAMP data were analysed using GraphPad Prism 7. Data represent
the mean ± standard error of the mean (SEM) of at least three inde-
pendent experiments. For time‐courses, data were normalized as a
percentage of the maximum forskolin response, and were plotted
against time, with the final pre‐incubation reading displayed at the
zero‐time point (time of vehicle/ligand addition). Concentration‐
response curves were generated by fitting non‐linear regressions to
data from indicated time points, which generated pEC50 and Emax
values. For Gαs data, the curves were expressed as a percentage of
maximum forskolin response, whereas for Gαi/o data, the curves
were expressed as a percentage of the forskolin response at the
same time point. Statistical significance was determined using an
unpaired t‐test or one‐way ANOVA.
2.6 | Molecular cloning of the CAMYEL biosensor
into lentiviral vector
A lentiviral vector containing the CAMYEL sequence under the con-
trol of the Ef1α promoter was cloned using Gateway technology
(Invitrogen). The CAMYEL‐coding sequence was flanked with Gate-
way‐compatible attB5 and attB2 sites and amplified by polymerase
chain reaction (PCR) using the forward primer 5′ GGGGACAAC
TTTGTATACAAAAGTTGACCATGATCACTCTCGGCATGGAC 3′ and
reverse primer 5′ GGGGACCACTTTGTACAAGAAAGCTGGGTAT-
TACTGCTCGTTCTTCAGCACTC 3′. The PCR product was gel puri-
fied and cloned into the pDONR 221 P5‐P2 vector using BP
Clonase II, to create the pENTR L5‐L2 CAMYEL entry clone. The
entry clone was sequenced using Sanger sequencing to confirm the
sequence was correct. Our pENTR L1‐R5 Ef1α entry clone was
cloned along with the pENTR L5‐L2 CAMYEL entry clone into the
pLenti X1 Zeo DEST vector32 using LR Clonase II, to create the
pLenti X1 Ef1α CAMYEL expression clone.
2.7 | Production of the THP‐1 CAMYEL stable cell
lines
For transduction of THP‐1 suspension cells with CAMYEL lentivirus,
a spinoculation protocol using purified lentivirus was followed.
HEK293T cells were seeded on five 20 cm2 dishes at 12 million
cells per dish. The following day, cells were transfected with the
pLenti X1 Ef1α CAMYEL lentiviral vector and the lentiviral packag-
ing and envelope plasmids pMDL, pRSV‐Rev, and pCMV‐VSV‐G,
using Lipofectamine 2000. After 2 days, media containing secreted
lentivirus was harvested and spun at 2000 RPM for 5 minutes, and
supernatant containing lentivirus was filtered through a 0.45 μm fil-
ter and spun at 20 000 RPM at 4°C for 2.5 hours to concentrate
the virus. Supernatant was removed and virus was resuspended in
50 μL of cold PBS per tube and stored at −80°C. 400 000 THP‐1
cells in 2 mL of cell culture medium were transduced with 2 μL of
purified lentivirus and 4 μg mL−1 hexadimethrine bromide (Poly-
brene) for 20 minutes at room temperature, then centrifuged for
30 minutes at 800 rpm. The cell pellet was resuspended in media
and cultured for 3 days before fluorescence‐activated cell sorting
(FACS) analysis using a Becton Dickinson FACS Aria III to select
viable cells that expressed CAMYEL (based on fluorescence of the
YFP) and sort them into three expression levels (low, medium, and
high). DAPI was used to stain dead cells, which were detected by
laser excitation at 405 nm and emission at 450/40 nm, and were
removed by gating. From the population of live single cells, YFP
fluorescence was measured by laser excitation at 488 nm and emis-
sion at 530/30 nm.
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2.8 | Flow cytometry analysis and fluorescent
ligand binding assay
A sample of the same HEK293A parental and ΔGαs cells that were
co‐transfected with CAMYEL and RXFP1 and used for BRET assays,
along with untransfected control cells, were detached from a plate
and analysed using flow cytometry to confirm co‐expression of
CAMYEL (by YFP expression) and RXFP1 (by fluorescent ligand bind-
ing), using a Beckman Coulter CytoFLEX S. To show specific RXFP1
binding cells were washed and resuspended in DPBS containing 1%
bovine serum albumin (BSA) and incubated either alone, with
TAMRA‐labeled H2 relaxin (20 nmol L−1), or with TAMRA‐labeled
H2 relaxin and an excess of unlabeled H2 relaxin (2 μmol L−1), for
30 minutes at room temperature. Unbound relaxin was removed by
centrifugation, and cells were resuspended in cold 1% BSA DPBS
containing DAPI, and used for flow cytometry. Live cells expressing
YFP and TAMRA were isolated as above, but with a few differences.
DAPI emission was measured at 450/45 nm, YFP emission was mea-
sured at 525/40 nm, and TAMRA was measured by laser excitation
at 561 nm and emission at 585/42. A quadrant gate was used to
show there was a subpopulation of cells expressing YFP and binding
TAMRA‐labeled relaxin. Data were analysed using FlowJo 10.
3 | RESULTS
3.1 | Detection of cAMP activity at RXFP1
To establish the range of intracellular cAMP activity that can be
detected using CAMYEL HEK‐RXFP1 cells transiently transfected
with CAMYEL were stimulated with a range of concentrations of
forskolin, a diterpene that directly activates adenylate cyclase.33
HEK‐RXFP1 cells showed fast, concentration‐dependent increases in
cAMP activity that peaked at about 5‐10 minutes and were sus-
tained over 45 minutes (Figure 1A). A concentration‐response curve
generated for 45 minutes showed a potency (pEC50) of 6.77 ± 0.07
(Figure 1B) and a maximal response at 10 μmol L−1 forskolin.
After establishing that CAMYEL can detect concentration‐depen-
dent increases in cAMP activity in HEK‐RXFP1 cells, we investigated
F IGURE 1 Ligand‐induced cAMP activity in HEK‐RXFP1 cells. HEK293T cells stably expressing RXFP1 were stimulated with vehicle,
forskolin, or an RXFP1 agonist for 45 minutes. (A) Time‐course of forskolin‐induced cAMP activity. (B) Concentration‐response curve for
forskolin at 45 minutes. Time‐course for (C) H2 relaxin‐ and (D) ML290‐induced cAMP activity. (E) Concentration‐response curves for H2
relaxin and ML290 at 5 and 45 minutes. Time of ligand or vehicle addition is represented by an arrow. Data represent mean ± SEM of three
independent experiments
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agonist activation. Stimulation with the native ligand H2 relaxin or
ML29021 showed concentration‐dependent cAMP increases that also
plateaued by 5‐10 minutes and were maintained for 45 minutes (Fig-
ure 1C and D). The responses approached or reached the maximum
forskolin response, suggesting they are approaching the detection
limit of the sensor. Notably, sub‐maximal concentrations of ML290
showed slow decreases in cAMP activity after peaking at about 5
minutes. Concentration‐response curves were generated for five and
45 minutes to compare ligand efficacy and potency values over time
(Figure 1E, Table 1). Ligand efficacy was greater at 45 minutes com-
pared to 5 minutes and was similar for both ligands. However, the
potency of H2 relaxin was >10 000 times higher than that of
ML290 at both time points (P < 0.01).
3.2 | Detection of cAMP activity at RXFP2
A forskolin time‐course in HEK‐RXFP2 cells showed a similar profile
to that seen in HEK‐RXFP1 cells, with rapid cAMP activity increases
that became stable after 5‐10 minutes and were sustained for 45 min-
utes (Figure 2A). A concentration‐response curve for forskolin at
45 minutes showed a potency (pEC50) of 5.92 ± 0.08 (Figure 2B),
which was nearly ten times lower than that seen in the HEK‐RXFP1
cells (P < 0.01), despite being isolated from the same parental cell line.
Stimulation of HEK‐RXFP2 cells with the native ligand INSL3 or
H2 relaxin (which also activates RXFP2) induced concentration‐
dependent increases in cAMP activity which approached the forsko-
lin maximum response more slowly than agonists in HEK‐RXFP1 cells
(Figure 2C and D). The two ligands showed different temporal pat-
terns of cAMP activity which was most evident at sub‐maximal con-
centrations where INSL3 showed slow, sustained increases, whereas
equivalent concentrations of H2 relaxin produced fast cAMP
increases to 5 minutes which were then sustained. These differences
were evident in concentration‐response curves generated at 5 and
45 minutes whereby the potency of INSL3 increased nearly 10‐fold
between 5 and 45 minutes (P < 0.01), whereas the potency of
relaxin stayed relatively stable for the duration of the time‐course
(Figure 2E, Table 2).
As stimulation of HEK‐RXFP1 and HEK‐RXFP2 both demonstrate
rapid and sustained increases in cAMP, it is possible that the
CAMYEL sensor is not dynamic and does not easily reverse the con-
formational change that occurs when cAMP binds. To simply assess
whether the sensor was able to respond to rapid changes in cAMP
we utilized a specific receptor antagonist. As there is no relevant
RXFP1 antagonist we utilized a well‐characterized RXFP2 antagonist
INSL3 B‐chain dimer.22 Blockade of RXFP2 by the antagonist
10 minutes before adding the agonist INSL3 abolished the ability of
INSL3 to increase cAMP activity (Figure 2F). Importantly, addition of
antagonist 10 minutes after addition of INSL3 resulted in real‐time
reversal of the BRET signal highlighting the CAMYEL sensor is able
to respond to dynamic changes in cAMP activity.
3.3 | Inhibition of cAMP activity at RXFP3
We further validated the use of the CAMYEL assay for the Gαi/o‐
coupled RXFP receptors, starting with RXFP3. As Gαi/o‐coupled
receptors inhibit adenylate cyclase to reduce cAMP activity, we
stimulated cells with forskolin and measured inhibition of forskolin‐
stimulated cAMP. CHO‐RXFP3 cells transiently expressing CAMYEL
were stimulated with either analogue 2 or peptide 5 for 4 minutes,
before forskolin was added. 10 μmol L−1 forskolin was used, as it
is the approximate EC50 for cAMP response in these cells (Fig-
ure S1), and has been used previously for measuring cAMP inhibi-
tion using CAMYEL in CHO cells at other GPCRs.19,34 The two
agonists showed similar, concentration‐dependent cAMP inhibition
profiles (Figure 3A and B). Complete or near‐complete inhibition
was reached by higher concentrations of agonist (100 nmol L−1‐
10 μmol L−1) at about 20‐25 minutes, before cAMP activity started
to slowly increase again. Inhibitory concentration‐response curves
were generated for 10 and 45 minutes, expressed as a percentage
of forskolin at each time point (Figure 3C, Table 3). Notably, ligand
efficacy was not different at 10 or 45 minutes however, peptide 5
demonstrated greater potency at 45 minutes than at 10 minutes
and was more potent than analogue 2 only at 45 minutes
(P < 0.05).
As our lab also had HEK‐RXFP3 cells, they were also tested for
agonist‐induced cAMP inhibition together with another agonist, R3/
I5. Forskolin is more potent in HEK293T than CHO‐K1 cells, so we
used a lower concentration (500 nmol L−1, ~EC50) to allow detection
of agonist‐induced inhibition (Figure S2). All agonists showed con-
centration‐dependent inhibition of forskolin‐stimulated cAMP, which
reached maximum inhibition after about 15‐20 minutes and, unlike
in CHO‐RXFP3 cells, were sustained for the duration of the time‐
course (Figure 3D‐F). All the ligands demonstrated lower efficacy
than in CHO‐RXFP3 cells especially R3/I5 which had significantly
lower efficacy than the other ligands but only at 10 minutes (Fig-
ure 3G, Table 4). Importantly this ligand is not a partial agonist of
cAMP activation9 and the data may reflect the strong potency of
forskolin in HEK cells and the R3/I5 data stimulations being per-
formed at a later time to the other agonists. Notably R3/I5 potency
was the same as the other ligands as expected from previous data
although the data from analogue 2 at 45 minutes was not of suffi-
cient quality to generate accurate curve fits in Prism.
TABLE 1 Efficacy and potency of agonists acting at RXFP1
Time point H2 relaxin ML290
Emax (% maximum
forskolin)
5 minutes 65.65 ± 2.21 71.32 ± 2.02
45 minutes 91.58 ± 1.84* 85.22 ± 2.72**
pEC50 5 minutes 10.43 ± 0.08 6.54 ± 0.08***
45 minutes 10.71 ± 0.05 6.05 ± 0.06***
HEK‐RXFP1 cells were stimulated for 45 minutes with ML290 or H2
relaxin. The efficacy (Emax) and potency (pEC50) were determined at 5
and 45 minutes. Efficacy is expressed as a percentage of the maximum
response to forskolin (10 μmol L−1). Data represent mean ± SEM of three
independent experiments. *P < 0.01 compared to 5 minutes; **P < 0.05
compared to 5 minutes; ***P < 0.01 compared to H2 relaxin (unpaired
t‐tests).
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3.4 | Modulation of CAMYEL signal using Gαi/o
inhibition and antagonist
We also demonstrated the ability to inhibit or reverse the BRET signal
at a Gαi/o receptor, in HEK‐RXFP3 cells. Treatment with the Gαi/o inhi-
bitor pertussis toxin (PTX) (100 ng mL−1; 20 hours) abolished the
ability of R3/I5 to inhibit forskolin‐induced cAMP activity at RXFP3
(Figure 4A). Treatment with the antagonist R3 B1‐22R (10 μmol L−1)
after stimulation with agonist (30 minutes) rapidly reversed the BRET
signal (Figure 4B), again demonstrating that we are able to measure
dynamic cAMP changes using the CAMYEL sensor.
3.5 | Inhibition of cAMP activity at RXFP4
Finally, in our initial characterisation of CAMYEL in recombinant
cells, we tested the ability of agonists to inhibit cAMP activity at
RXFP4. We only had CHO‐K1 cells stably expressing RXFP4
(CHO‐RXFP4) available, and tested the native ligand INSL5 and
analogue 13.26 As with CHO‐RXFP3, cells were pre‐incubated for
4 minutes with agonist, before adding forskolin at a concentration
of 10 μmol L−1, which is the approximate EC50 for forskolin in
these cells (Figure S3). The two agonists showed concentration‐
dependent decreases in cAMP activity, which plateaued after
about 30 minutes (Figure 5A and B). Concentration‐response
curves were generated for 10 and 45 minutes, expressed as a
F IGURE 2 Ligand‐induced cAMP activity in HEK‐RXFP2 cells. HEK293T cells stably expressing RXFP2 were stimulated with ligands for
45 minutes. (A) Time‐course of forskolin‐induced cAMP activity. (B) Concentration‐response curve for forskolin at 45 minutes. Time‐course for
(C) INSL3‐ and (D) H2 relaxin‐induced cAMP activity. (E) Concentration‐response curves for INSL3 and H2 relaxin at 5 and 45 minutes. (F)
Blocking and reversibility of the CAMYEL signal was demonstrated by adding an RXFP2 antagonist (INSL3 B‐chain dimer) 10 minutes before or
after agonist addition. Time of ligand or vehicle addition is represented by an arrow. Data represent mean ± SEM of three independent
experiments
TABLE 2 Efficacy and potency of agonists acting at RXFP2
Time point INSL3 H2 relaxin
Emax (% maximum
forskolin)
5 minutes 65.92 ± 3.94 57.79 ± 3.02
45 minutes 94.84 ± 2.89 87.53 ± 3.25
pEC50 5 minutes 8.65 ± 0.12 8.28 ± 0.13
45 minutes 9.58 ± 0.08* 8.18 ± 0.09**
HEK‐RXFP2 cells were stimulated for 45 minutes with INSL3 or H2
relaxin. The efficacy (Emax) and potency (pEC50) were determined at 5
and 45 minutes. Efficacy is expressed as a percentage of the maximum
response to forskolin (10 μmol L−1). Data represent mean ± SEM of three
independent experiments. *P < 0.01 compared to 5 minutes; **P < 0.01
compared to INSL3 (unpaired t‐tests).
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percentage of forskolin activity at the same time point (Figure 5C).
At 45 minutes, the efficacy of INSL5 was greater than that of
analogue 13 but this was not statistically significant (P > 0.05)
(Table 5). The lower efficacy of the ligands seen in these cells
compared to ligands in CHO‐RXFP3 cells may be related to the
lower expression of RXFP4 in the CHO‐RXFP4 cells. The potency
of INSL5 (8.58 ± 0.16) was not significantly higher than analogue
13 (7.75 ± 0.49) (P > 0.05).
F IGURE 3 Ligand‐induced cAMP activity in cells expressing RXFP3. CHO‐K1 and HEK293T cells stably expressing RXFP3 (CHO‐RXFP3
and HEK‐RXFP3) were stimulated with vehicle, forskolin, and an RXFP3 agonist for 45 minutes. CHO‐RXFP3 cells were stimulated with (A)
analogue 2 or (B) peptide 5, with addition of forskolin (10 μmol L−1) after 4 minutes. (C) Concentration‐response curves were generated for
CHO‐RXFP3 at 10 and 45 minutes. HEK‐RXFP3 cells were stimulated with (D) analogue 2, (E) peptide 5, or (C) R3/I5, with addition of forskolin
(500 nmol L−1) after five minutes. (F) Concentration‐response curves were generated for HEK‐RXFP3 cells at 10 and 45 minutes. Time of
agonist or vehicle (A) and forskolin or vehicle (F) addition are represented by arrows. Concentration‐response data is expressed as a percentage
of forskolin for the indicated time point. Data represent mean ± SEM of three independent experiments
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3.6 | Investigation of RXFP1 signaling in a native
expressing cell line using CAMYEL
So far, we have shown that CAMYEL can detect cAMP activity with
high sensitivity in cells that recombinantly overexpress the receptor
of interest. However, we have not demonstrated its use in cells that
natively express the receptor at lower levels. To enable the use of
CAMYEL in all types of mammalian cells, we cloned CAMYEL into
the pLenti X1 Zeo DEST vector under control of the constitutive
Ef1α promoter using Gateway cloning, to create the pLenti X1 Ef1α
CAMYEL expression clone (see Methods). We showed that transfec-
tion of this vector allows robust expression of CAMYEL (data not
shown) and therefore produced lentivirus for the transduction of
cells.
Human monocytic leukaemia THP‐1 cells have commonly been
used for detecting relaxin induced cAMP activity even though they
have low endogenous expression of RXFP1 (~275 receptors per
cell35), in contrast to HEK‐RXFP1 cells, which have ~50 000‐
100 000 receptors per cell.36 As THP‐1 cells are a non‐adherent cell
line we used a spinoculation protocol involving purified lentivirus to
transduce the cells, followed by sorting using FACS into populations
expressing low, medium, or high levels of CAMYEL (Figure 6). The
“high” CAMYEL population was initially tested for concentration‐
dependent increases in forskolin‐induced cAMP activity (Figure 7A).
Forskolin produced rapid dose‐dependent increases in cAMP with a
maximum response at 100 μmol L−1 and a higher potency at 5 min-
utes (5.29 ± 0.03) than at 45 minutes (4.93 ± 0.05) (P < 0.01) (Fig-
ure 7B).
Stimulation of the three sorted THP‐1 CAMYEL populations with
H2 relaxin for 45 minutes revealed robust concentration‐dependent
increases in cAMP activity (Figure 7C, E, G). The higher concentra-
tions of H2 relaxin (10 and 100 nmol L−1) showed more transient
responses than seen in HEK‐RXFP1 cells, as cAMP reached a maxi-
mum by 5 minutes before declining to less than half of the maximum
forskolin response. Notably, the response to H2 relaxin did not
approach or reach the maximal detectable response by the CAMYEL
in THP‐1 cells (Figure 7A). Concentration‐response curves were gen-
erated for 5 and 45 minutes to compare the three populations
TABLE 3 Efficacy and potency of agonists acting at RXFP3 in
CHO‐K1 cells
Time point Analogue 2 Peptide 5
Emax (% forskolin)
(bottom)
10 minutes 22.06 ± 2.54 20.42 ± 2.79
45 minutes 21.58 ± 3.93 29.4 ± 2.68
pEC50 10 minutes 7.98 ± 0.07 8.39 ± 1.00
45 minutes 8.21 ± 0.12 8.70 ± 0.11*
CHO‐RXFP3 cells were stimulated with agonist for 45 minutes, with
addition of forskolin four minutes after agonist addition. The efficacy
(Emax) and potency (pEC50) were determined at 10 and 45 minutes. Effi-
cacy is expressed as a percentage of the response to forskolin (10 μmol
L−1). Data represent mean ± SEM of three independent experiments.
*P < 0.05 compared to analogue 2 (unpaired t‐test).
TABLE 4 Efficacy and potency of agonists acting at RXFP3 in HEK293T cells
Time point Analogue 2 Peptide 5 R3/I5
Emax (% forskolin) (bottom) 10 minutes 34.27 ± 9.834 39.18 ± 7.80 64.77 ± 6.23
45 minutes 39.72 ± 10.82 50.57 ± 9.44 47.97 ± 4.61
pEC50 10 minutes 8.24 ± 0.36 8.52 ± 0.32 8.30 ± 0.43
45 minutes Ambiguous 9.68 ± 0.65 9.32 ± 0.26
HEK‐RXFP3 cells were stimulated with agonist for 45 minutes, with addition of forskolin 5 minutes after agonist addition. The efficacy (Emax) and
potency (pEC50) were determined at 10 and 45 minutes. Efficacy is expressed as a percentage of the response to forskolin (10 μmol L−1). Data repre-
sent mean ± SEM of three independent experiments.
F IGURE 4 Blocking and reversing the CAMYEL signal in HEK‐RXFP3 cells. (A) Pre‐treatment of HEK‐RXFP3 cells with the Gαi/o inhibitor
pertussis toxin (100 ng mL−1; 20 hours) abolished R3/I5‐induced inhibition of cAMP activity. (B) Treatment with the RXFP3 antagonist R3 B1‐
22R after stimulation with R3/I5 (30 minutes) and forskolin showed reversal of the R3/I5 response in real time. Time of ligand or vehicle
addition is represented by an arrow. Data represent the mean ± SEM of three independent experiments
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(Figure 7D, F, H). Notably, there was no difference in H2 relaxin effi-
cacy or potency between the cells, indicating the level of CAMYEL
had no effect on the response to H2 relaxin (Table 6). Ligand effi-
cacy was greater at 5 minutes as expected from the shape of the
response curves, but ligand potency was higher at 45 minutes
(P < 0.05).
Relaxin‐stimulated intracellular cAMP accumulation through
RXFP1 has been shown to be modulated by three G proteins. Imme-
diate increases in cAMP are mediated by Gαs and negatively modu-
lated by GαoB,10 whereas there is a delayed increase in cAMP
activity after ~15 minutes mediated by Gαi3 in a number of cell
types, including HEK‐RXFP1 and THP‐1.10,12,13 However, using the
CAMYEL assay we have not detected a biphasic increase in cAMP
activity at RXFP1. To investigate further, we tested the effect of
treatment with PTX (100 ng mL−1; 16‐18 hours) on H2 relaxin‐
induced cAMP activity over time in THP‐1 CAMYEL cells (Figure 8A
and B). Comparing the H2 relaxin responses as a percentage of the
forskolin response at 5 minutes showed a trend toward higher cAMP
activity in PTX‐treated cells at higher concentrations of H2 relaxin,
suggesting that PTX is inhibiting the GαoB inhibition, but this was
not significant (P > 0.05) (Figure 8C). At 45 minutes, there was no
difference between treated and untreated cells (Figure 8D),
F IGURE 5 Ligand‐induced cAMP activity in CHO‐RXFP4 cells. CHO‐K1 cells stably expressing RXFP4 (CHO‐RXFP4) were stimulated with
vehicle, forskolin, and an RXFP4 agonist for 45 minutes, with addition of forskolin (10 μmol L−1) 4 minutes after agonist addition. Time‐courses
were generated for (A) INSL5 and (B) analogue 13. (C) Concentration‐response curves were generated for both agonists at 10 and 45 minutes.
Time of agonist or vehicle (A) and forskolin or vehicle (F) addition are represented by arrows. Concentration‐response data is expressed as a
percentage of forskolin for the indicated time point. Data represent mean ± SEM of three independent experiments
TABLE 5 Efficacy and potency of agonists acting at RXFP4
Time point INSL5 Analogue 13
Emax (% forskolin) (bottom) 10 minutes 56.16 ± 3.92 65.51 ± 4.01
45 minutes 40.42 ± 5.91 56.52 ± 7.49
pEC50 10 minutes 8.05 ± 0.17 7.55 ± 0.28
45 minutes 8.58 ± 0.16 7.75 ± 0.49
CHO‐RXFP4 cells were stimulated with agonist for 45 minutes, with
addition of forskolin 4 minutes after agonist addition. The efficacy (Emax)
and potency (pEC50) were determined at 10 and 45 minutes. Efficacy is
expressed as a percentage of the response to forskolin (10 μmol L−1).
Data represent mean ± SEM of three independent experiments.
F IGURE 6 Representation of fluorescence‐activated cell sorting
(FACS) of transduced THP‐1 CAMYEL cells. THP‐1 cells were
transduced by spinoculation with CAMYEL lentivirus and were
sorted to remove untransduced cells. Single, live cells were isolated,
and sorted by expression of YFP into low, medium, and high levels
of CAMYEL expression, based on YFP fluorescence. Cells with YFP
expression that was no greater than control THP‐1 cells were
removed
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suggesting we are not seeing a delayed Gαi3‐mediated enhancement
of cAMP.
3.7 | Dissecting RXFP1 cAMP activity using
HEK293A ΔGαs cells
To further investigate this potential lack of Gαi3 cAMP effect we
used novel HEK293A cells with CRISPR/Cas9‐mediated knockout of
Gαs members (GNAS and GNAL genes).30 We first produced forskolin
concentration‐response data for the HEK293A parental and Gαs
knockout (ΔGαs) cells. HEK293A parental cells showed robust
increases in cAMP activity that were very similar to those seen ear-
lier in HEK293T cells expressing RXFP1 or RXFP2 (Figure 9A). How-
ever, the ΔGαs cells showed very weak cAMP activity, requiring
relatively high concentrations of forskolin (>10 μmol L−1) to detect a
cAMP increase, which was only transient (Figure 9B). As forskolin
has a lower affinity for adenylate cyclase in the absence of Gαs,37
we transfected Gαs into these cells to show that forskolin potency
could be rescued by re‐expression of Gαs (Figure 9C). At 45 minutes,
the potency of forskolin in HEK293A parental cells was 5.91 ± 0.04.
In ΔGαs cells with re‐expression of Gαs, the potency was 7.1 ± 1.29
(Figure 9D).
TABLE 6 Efficacy and potency of H2 relaxin in the THP‐1 CAMYEL stable cell line
Time point Low CAMYEL Medium CAMYEL High CAMYEL
Emax (% maximum forskolin) 5 minutes 86.11 ± 2.23 69.29 ± 2.52 80.02 ± 2.93
45 minutes 41.61 ± 2.29* 32.15 ± 1.87* 38.64 ± 1.77*
pEC50 5 minutes 9.10 ± 0.09 9.15 ± 0.08 9.23 ± 0.08
45 minutes 9.67 ± 0.15* 9.80 ± 0.21* 9.77 ± 0.10*
THP‐1 CAMYEL cells sorted into three levels (high, medium, low) of CAMYEL expression were stimulated with H2 relaxin for 45 minutes. The efficacy
(Emax) and potency (pEC50) was determined for each expression level at 5 and 45 minutes. Efficacy is expressed as a percentage of the maximum
response to forskolin (10 μmol L−1), with vehicle expressed as 0%. Data represent mean ± SEM of three independent experiments. *P < 0.05 compared
to 5 minutes (unpaired t‐test).
F IGURE 8 Effect of pertussis toxin on cAMP activity in THP‐1 CAMYEL cells. THP‐1 CAMYEL (high expression) were either (A) untreated or
(B) treated with pertussis toxin (100 ng mL−1; 16‐18 hours), and stimulated with vehicle, forskolin, or H2 relaxin for 45 minutes. Treated and
untreated cells were compared at (C) 5 and (D) 45 minutes. Time of ligand or vehicle addition is expressed by an arrow. Data in (C) and (D) are
expressed as a percentage of the forskolin response at the same time point. Data represent the mean ± SEM of four independent experiments
F IGURE 7 Ligand‐induced cAMP activity in THP‐1 CAMYEL cells. THP‐1 cells that endogenously express RXFP1 and stably express high,
medium, or low levels of CAMYEL (THP‐1 CAMYEL) were stimulated with vehicle, forskolin, or H2 relaxin for 45 minutes. (A) Time‐course for
forskolin activity in high expression cells. (B) Concentration‐response curves for forskolin at 5 and 45 minutes. (C, E, G) Time‐courses for H2
relaxin‐induced cAMP activation in the low‐, medium‐, and high‐expressing cells. (D, F, H) Concentration‐response curves for H2 relaxin at 5
and 45 minutes in the low‐, medium‐, and high‐expressing cells. Time of ligand or vehicle addition is represented by an arrow. Data represent
mean ± SEM of three independent experiments
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Parental HEK293A and ΔGαs cells were then transiently co‐
transfected with CAMYEL and RXFP1 to detect the Gαi3‐mediated
phase of cAMP activity. Isoprenaline (10 μmol L−1), which targets
Gαs‐coupled β‐adrenoceptors endogenous to HEK293 cells, was used
as a control for these experiments to confirm lack of Gαs activity. As
expected, the response to isoprenaline was robust in the parental
cells (Figure 9E), but was abolished in the ΔGαs cells (Figure 9F).
Similarly, the response to H2 relaxin (100 pmol L−1‐100 nmol L−1)
was robust in parental cells, but was completely abolished in the
ΔGαs cells. To test whether pre‐activation of adenylate cyclase is
required to detect the delayed Gαi3‐mediated phase of cAMP activ-
ity, we primed the ΔGαs cells with forskolin (33 μmol L−1) to com-
pensate for the loss of Gαs, before adding the ligands (Figure 9G).
However, no response to H2 relaxin was detectable. Additionally,
we used flow cytometry to confirm that a subpopulation of cells
from the same transfected population used in the assay were co‐
expressing CAMYEL (by YFP expression of the sensor) and RXFP1
(by binding of fluorescent TAMRA‐H2 relaxin) (Figure S4), demon-
strating that the lack of response is not due to CAMYEL and RXFP1
not being present in the same cells.
F IGURE 9 cAMP activity in HEK293A parental and Gαs knockout (ΔGαs) cells. (A) HEK293A parental cells, (B) HEK293A ΔGαs cells, and (C)
HEK293A ΔGαs cells with Gαs transfected in, were transfected with CAMYEL and stimulated with vehicle or forskolin for 45 minutes. (D)
Concentration‐response curves were generated for forskolin at 5 and 45 minutes. (E) HEK293A parental and (F) HEK293A ΔGαs cells were co‐
transfected with CAMYEL and RXFP1, and were stimulated with vehicle, forskolin, isoprenaline, or H2 relaxin for 45 minutes. (G) HEK293A
ΔGαs cells were primed with forskolin (33 μmol L−1) to compensate for the loss of Gαs, before adding forskolin, isoprenaline, or H2 relaxin.
Time of ligand or vehicle addition is represented by an arrow. Data represent mean ± SEM of three independent experiments
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4 | DISCUSSION
Biased signaling is the ability of a ligand to selectively activate particu-
lar signaling pathways downstream of a GPCR in the same cell type,
compared to the endogenous ligand. Biased signaling has been shown
to occur at relaxin family peptide receptors. For example, at RXFP1,
H2 relaxin promotes ERK1/2 activation but ML290 does not.16 Relat-
edly, system bias has been shown, particularly for RXFP1. For example,
HEK‐RXFP1 cells signal via cAMP but not cGMP, whereas fibroblasts
that natively express RXFP1 signal via cGMP but not cAMP, and
human vascular cells that express RXFP1 signal through both.16 Mea-
suring the temporal aspects of signaling facilitates accurate detection
of biased ligands,19 and the use of native cells will facilitate under-
standing of how relaxin family peptide receptors signal in different cell
backgrounds. Therefore, in this study, we set out to demonstrate the
use of the BRET‐based biosensor CAMYEL for real‐time cAMP signal-
ing at relaxin family peptide receptors, initially in recombinant cells,
but with the goal of detecting cAMP in native cells.
RXFP receptor signaling has typically been measured in HEK293T
or CHO‐K1 cells expressing the receptor of interest, using traditional
end point cAMP assays, such as a cAMP response element (CRE) repor-
ter gene assay, or accumulation kits including AlphaScreen and Homo-
geneous Time Resolved Fluorescence (HTRF). However, the CRE
reporter gene assay provides a readout of total downstream activity
from a combination of signaling pathways, including cAMP/PKA, Ca2+/
CaM, Ras/ERK, and PI3K/Akt,38 and is therefore inappropriate for
detecting bias. Although kit‐based assays directly measure cAMP, they
are laborious and involve stimulations in the presence of phosphodi-
esterase inhibitors to stop the degradation of cAMP, and therefore do
not reveal the kinetics of cAMP activity. We have demonstrated that
CAMYEL is a sensitive and robust alternative for detecting real‐time
cAMP activity in cells in the absence of phosphodiesterase inhibitors.
Notably, we were able to detect both Gαs‐mediated cAMP activation
and Gαi/o‐mediated cAMP inhibition for all RXFP receptors and multi-
ple cell types, including recombinant and native cells. At the Gαs‐
coupled RXFP1 and RXFP2 stably expressed in HEK293T cells, we
showed sustained concentration‐dependent increases in cAMP activity
that differed over time between the agonists. At RXFP3 and RXFP4
expressed in CHO‐K1 or HEK293T cells, we showed sustained concen-
tration‐dependent inhibition of forskolin‐stimulated cAMP activity,
with more similar patterns of cAMP inhibition induced by agonists.
Agonists at the four receptors also showed similar potencies to those
already seen using traditional cAMP end point assays.
The sustained cAMP activity seen at RXFP1 and RXFP2 is consis-
tent with the finding that these receptors lack β‐arrestin‐mediated
desensitization and show poor internalization in response to ligand stim-
ulation.39 However, we also saw sustained cAMP inhibition at RXFP3
(particularly in HEK293T cells) and RXFP4, which have been shown to
interact with β‐arrestins and internalize after stimulation with their
endogenous ligands.14,15 Although the original characterization of
CAMYEL in RAW 264.7 murine macrophage cells showed that CAMYEL
can report substantial and rapid decreases in BRET signal,20 studies on
some GPCRs, including the cannabinoid 1,40 dopamine D2L,
19 and mu‐
opioid34 receptors, have also shown relatively sustained changes in
CAMYEL signal over extended periods of time. However, most studies
using CAMYEL do not show time‐course data and some include phos-
phodiesterase inhibitors in the assay to stop the breakdown of cAMP.
As sustained changes in the BRET signal have been observed in the pre-
sent study and other studies, it was thought possible that cAMP does
not easily dissociate from the sensor, or that the sensor does not easily
reverse its conformation and therefore does not precisely detect real‐
time fluctuations in cAMP levels. Therefore, we demonstrated reversibil-
ity of the BRET signal at RXFP2 and RXFP3 by adding an antagonist
after pre‐incubation with agonist, which both showed real‐time reversal
of the signal. These experiments demonstrated that the sensor is
dynamic and able to detect changes in BRET signal reflective of changes
in cAMP levels, over extended periods of time.
Targeting RXFP receptors with drugs has potential for a range of
therapeutic applications (reviewed in 4). Much effort has therefore been
put into designing analogues of relaxin family peptides, including ago-
nists and antagonists used in the present study.41 In particular, RXFP1 is
a promising therapeutic target for cardiovascular diseases and fibrosis.
Novel ligands acting at RXFP1, including peptide analogues (e.g., 42) and
small molecules,21 have been screened in THP‐1 cells due to the robust
cAMP activation by relaxin in these cells. Our newly‐developed THP‐1
CAMYEL cell line will be a valuable tool for drug discovery targeting
RXFP1, as it is sensitive and able to detect concentration‐dependent
increases in cAMP activity over time in the absence of phosphodi-
esterase inhibitors. Importantly, the assay showed a similar potency of
H2 relaxin to that observed using traditional cAMP assays such as
enzyme immunoassay43 and HTRF cAMP assays.42 The THP‐1 CAMYEL
assay also streamlines the process of screening ligands, as these suspen-
sion cells can be plated out on the day of the assay, and no extra steps
for lysis or addition of detection reagents are required. Additionally,
while recombinant HEK‐RXFP1 cells showed cAMP responses that
reached or closely approached the ceiling set by forskolin, the native
THP‐1 CAMYEL cells showed that the level of agonist‐induced cAMP
activity was clearly within the dynamic range of the assay. The sorted
THP‐1 CAMYEL cells also showed that the level of biosensor present in
the cells did not affect the observed potency of H2 relaxin, suggesting
that the expression level of CAMYEL is of little importance and does not
need to be tightly controlled. The successful use of CAMYEL in a cell
line that has low RXFP1 expression also suggests that the lentiviral
CAMYEL construct can be utilized to transduce other native cells,
including human primary cells, in order to understand RXFP1 signaling in
the context of human diseases.
RXFP1 has been shown to couple to at least three G proteins to
modulate cAMP activity in some human cells. Gαs is the primary media-
tor of cAMP, and its actions are negatively modulated by GαoB.10 Fur-
ther increases in cAMP activity have also been shown to occur in a
number of cell types, including THP‐1,13 HEK‐RXFP1,10 and some
human primary vascular cell types44 downstream of Gαi3, Gβγ, PI3K,
PKCζ, and adenylate cyclase 5.10,12,13 Coupling of RXFP1 to Gαi3 has
also been confirmed by BRET protein‐protein interaction studies,16 and
is dependent on localization of RXFP1 and Gαi/o in membrane raft
microdomains.45 This finding suggests that cAMP activity at RXFP1 is
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compartmentalized, which is consistent with the finding that in HEK‐
RXFP1 cells, Gαs‐induced cAMP activity affects CRE transcription,
whereas Gαi3‐induced cAMP activity affects NFκB transcription.46 In
the present study, PTX inhibition in THP‐1 CAMYEL cells demonstrated
a potential inhibition by GαoB at 5 minutes which was not significant but
no effect at any other time point indicated a complete absence of a Gαi3
effect. We then used HEK293A cells that do not express the Gαs sub-
unit to further investigate. Although the potency of forskolin was dimin-
ished in these cells, re‐expression of Gαs restored the potency of
forskolin, showing that the diminished forskolin response was not an
off‐target effect of the gene editing in these cells. However, stimulation
of these cells with H2 relaxin when RXFP1 and CAMYEL were co‐
expressed did not show any increases in cAMP activity, including when
adenylate cyclase was primed using forskolin to compensate for the loss
of Gαs. Therefore, we have been unable to reproduce the Gαi3‐mediated
increase in cAMP activity at RXFP1 using the CAMYEL assay. It is there-
fore possible that there is a localized pool of cAMP that CAMYEL is
unable to detect. The original paper that described CAMYEL20 sug-
gested that CAMYEL is expressed throughout the cytoplasm, as it uses
a cytosolic mutant of Epac1.47 Further studies have shown cytosolic dis-
tribution of CAMYEL via confocal microscopy and western blot.48 We
have confirmed this using confocal microscopy in HEK293T cells stably
expressing CAMYEL (data not shown). Importantly, there is precedent
for the inability of cytosolic biosensors to detect localized hotspots of
cAMP activity. For example, in GH3B6 cells treated with vasoactive
intestinal peptide, FRET‐based biosensors for cAMP activity located
around the cytosol or localized to the plasma membrane reported robust
cAMP increases that were not detected by an AC8‐localized sensor.49 In
contrast, increases in cAMP activity after stimulation with thyrotropin‐
releasing hormone were detected by the AC8‐localized sensor but not
the cytosolic or membrane forms.49
In summary, CAMYEL is a valuable tool for the direct detection of
real‐time cAMP activity at the relaxin family peptide receptors 1‐4. We
have shown robust cAMP activation and inhibition at Gαs‐ and Gαi/o‐
coupled receptors when CAMYEL was transfected into recombinant cell
lines, and have also shown robust cAMP activity in a cell line that
expresses low native levels of RXFP1, when CAMYEL was delivered
virally. We have also detected differences in cAMP activity between dif-
ferent ligands and cell types, which can be modulated by antagonists and
an inhibitor. However, we could not replicate the biphasic cAMP
response at RXFP1 using this assay, which may suggest compartmental-
ization of cAMP activity at RXFP1, consistent with previous findings. The
development of a lentiviral CAMYEL construct will allow the transduction
of any mammalian cell for the real‐time analysis of cAMP signaling.
ACKNOWLEDGEMENTS
This research was supported by National Health and Medical
Research Council of Australia project grants [1100676] and
[1043750] (RADB) and the Victorian Government Operational Infras-
tructure Support Program. AI was funded by Japan Agency for Medi-
cal Research and Development (AMED) Grant Number
JP17gm5910013 and Japan Society for the Promotion of Science
(JSPS) KAKENHI Grant Number 17K08264. RADB is supported by an
NHMRC Research Fellowship. The authors thank Tania Ferraro and
Sharon Layfield for technical assistance; Dr Michelle Halls and Dr
Meritxell Canals (Monash Institute of Pharmacological Sciences, Park-
ville, Victoria, Australia) for helpful suggestions on the manuscript and
provision of the CAMYEL plasmid, respectively; and V. Jameson and
J. Kie (MBC Flow Cytometry Facility) for assistance with FACS.
DISCLOSURES
The authors declare that they have no conflicts of interest with the
contents of this article.
ORCID
Ross A. D. Bathgate http://orcid.org/0000-0001-6301-861X
REFERENCES
1. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new
tricks: biasing seven‐transmembrane receptors. Nat Rev Drug Discov.
2010;9:373‐386.
2. Smith JS, Lefkowitz RJ, Rajagopal S. Biased signalling: from simple
switches to allosteric microprocessors. Nat Rev Drug Discov. 2018;
17:243‐260.
3. Bathgate RA, Kocan M, Scott DJ, et al. The relaxin receptor as a
therapeutic target – perspectives from evolution and drug targeting.
Pharmacol Ther. 2018;187:114‐132.
4. Bathgate RAD, Halls ML, van der Westhuizen ET, Callander GE,
Kocan M, Summers RJ. Relaxin family peptides and their receptors.
Physiol Rev. 2013;93:405‐480.
5. Bathgate RA, Ivell R, Sanborn BM, Sherwood OD, Summers RJ. Inter-
national Union of Pharmacology LVII: recommendations for the
nomenclature of receptors for relaxin family peptides. Pharmacol Rev.
2006;58:7‐31.
6. Hsu SY, Nakabayashi K, Nishi S, et al. Activation of orphan receptors
by the hormone relaxin. Science. 2002;295:671‐674.
7. Kumagai J, Hsu SY, Matsumi H, et al. INSL3/Leydig insulin‐like pep-
tide activates the LGR8 receptor important in testis descent. J Biol
Chem. 2002;277:31283‐31286.
8. Liu C, Eriste E, Sutton S, et al. Identification of relaxin‐3/INSL7 as an
endogenous ligand for the orphan G‐protein‐coupled receptor
GPCR135. J Biol Chem. 2003;278:50754‐50764.
9. Liu C, Kuei C, Sutton S, et al. INSL5 is a high affinity specific agonist
for GPCR142 (GPR100). J Biol Chem. 2005;280:292‐300.
10. Halls ML, Bathgate RAD, Summers RJ. Relaxin family peptide recep-
tors RXFP1 and RXFP2 modulate cAMP signaling by distinct mecha-
nisms. Mol Pharmacol. 2006;70:214‐226.
11. Nguyen BT, Dessauer CW. Relaxin stimulates cAMP production in
MCF‐7 cells upon overexpression of type V adenylyl cyclase. Ann N
Y Acad Sci. 2005a;1041:296‐299.
12. Nguyen BT, Dessauer CW. Relaxin stimulates protein kinase C ζ
translocation: requirement for cyclic adenosine 3′,5′‐monophosphate
production. Mol Endocrinol. 2005b;19:1012‐1023.
13. Nguyen BT, Yang L, Sanborn BM, Dessauer CW. Phosphoinositide 3‐
kinase activity is required for biphasic stimulation of cyclic adenosine
3′,5′‐monophosphate by relaxin. Mol Endocrinol. 2003;17:1075‐1084.
14. Ang SY, Hutchinson DS, Patil N, et al. Signal transduction pathways
activated by insulin‐like peptide 5 at the relaxin family peptide
RXFP4 receptor. Br J Pharmacol. 2016;174:1077‐1089.
14 of 15 | VALKOVIC ET AL.
15. Kocan M, Sarwar M, Hossain MA, Wade JD, Summers RJ. Signalling
profiles of H3 relaxin, H2 relaxin and R3(BΔ23‐27)R/I5 acting at the
relaxin family peptide receptor 3 (RXFP3). Br J Pharmacol. 2014;171:
2827‐2841.
16. Kocan M, Sarwar M, Ang SY, et al. ML290 is a biased allosteric ago-
nist at the relaxin receptor RXFP1. Sci Rep. 2017;7:2968.
17. Mookerjee I, Hewitson TD, Halls ML, et al. Relaxin inhibits renal
myofibroblast differentiation via RXFP1, the nitric oxide pathway,
and Smad2. FASEB J. 2009;23:1219‐1229.
18. Samuel CS, Unemori EN, Mookerjee I, et al. Relaxin modulates car-
diac fibroblast proliferation, differentiation, and collagen production
and reverses cardiac fibrosis in vivo. Endocrinology. 2004;145:4125‐
4133.
19. Klein Herenbrink C, Sykes DA, Donthamsetti P, et al. The role of
kinetic context in apparent biased agonism at GPCRs. Nat Commun.
2016;7:10842.
20. Jiang LI, Collins J, Davis R, et al. Use of a cAMP BRET sensor to
characterize a novel regulation of cAMP by the sphingosine 1‐phos-
phate/G13 pathway. J Biol Chem. 2007;282:10576‐10584.
21. Xiao J, Huang Z, Chen CZ, et al. Identification and optimization of
small‐molecule agonists of the human relaxin hormone receptor
RXFP1. Nat Commun. 2013;4:1953.
22. Shabanpoor F, Zhang S, Hughes RA, et al. Design and development
of analogues of dimers of insulin‐like peptide 3 B‐chain as high‐affi-
nity antagonists of the RXFP2 receptor. Biopolymers. 2011;96:81‐87.
23. Shabanpoor F, Hossain M, Ryan P, et al. Minimization of relaxin‐3
leading to high affinity analogues with increased selectivity for
relaxin‐family peptide 3 receptor (RXFP3) over RXFP1. J Med Chem.
2012;55:1671‐1681.
24. Hojo K, Hossain MA, Tailhades J, et al. Development of a single‐
chain peptide agonist of the relaxin‐3 receptor RXFP3 using hydro-
carbon stapling. J Med Chem. 2016;59:7445‐7456.
25. Haugaard‐Kedström L, Shabanpoor F, Hossain M, et al. Design, synth-
esis and characterization of a single-chain peptide antagonist for the
relaxin‐3 receptor RXFP3. J Am Chem Soc. 2011;133:4965‐4974.
26. Patil NA, Hughes RA, Rosengren KJ, et al. Engineering of a novel
simplified human insulin‐like peptide 5 agonist. J Med Chem.
2016;59:2118‐2125.
27. Hossain MA, Bathgate RAD, Kong CK, et al. Synthesis, conformation,
and activity of human insulin‐like peptide 5 (INSL5). ChemBioChem.
2008;9:1816‐1822.
28. van der Westhuizen ET, Werry TD, Sexton PM, Summers RJ. The
relaxin family peptide receptor 3 activates extracellular signal‐regu-
lated kinase 1/2 through a protein kinase C‐dependent mechanism.
Mol Pharmacol. 2007;71:1618‐1629.
29. Belgi A, Bathgate RAD, Kocan M, et al. Minimum active structure of
insulin‐like peptide 5. J Med Chem. 2013;56:9509‐9516.
30. Stallaert W, van der Westhuizen ET, Schönegge A-M, et al. Puriner-
gic receptor transactivation by the β2‐adrenergic receptor increases
intracellular Ca2 + in nonexcitable cells. Mol Pharmacol. 2017;91:
533‐544.
31. Kocan M, See HB, Seeber RM, Eidne KA, Pfleger KDG. Demonstra-
tion of improvements to the bioluminescence resonance energy
transfer (BRET) technology for the monitoring of G protein‐coupled
receptors in live cells. J Biomol Screen. 2008;13:888‐898.
32. Campeau E, Ruhl VE, Rodier F, et al. A versatile viral system for
expression and depletion of proteins in mammalian cells. PLoS ONE.
2009;4:e6529.
33. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene acti-
vator of adenylate cyclase in membranes and in intact cells. Proc
Natl Acad Sci. 1981;78:3363‐3367.
34. Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A,
Canals M. Systematic analysis of factors influencing observations of
biased agonism at the mu‐opioid receptor. Biochem Pharmacol.
2016;113:70‐87.
35. Parsell DA, Mak JY, Amento EP, Unemori EN. Relaxin binds to and
elicits a response from cells of the human monocytic cell line, THP‐
1. J Biol Chem. 1996;271:27936‐27941.
36. Sudo S, Kumagai J, Nishi S, et al. H3 relaxin is a specific ligand for
LGR7 and activates the receptor by interacting with both the ecto-
domain and the exoloop 2. J Biol Chem. 2003;278:7855‐7862.
37. Dessauer CW, Scully TT, Gilman AG. Interactions of forskolin and
ATP with the cytosolic domains of mammalian adenylyl cyclase. J
Biol Chem. 1997;272:22272‐22277.
38. Lonze BE, Ginty DD. Function and regulation of CREB family tran-
scription factors in the nervous system. Neuron. 2002;35:605‐623.
39. Callander GE, Thomas WG, Bathgate RAD. Prolonged RXFP1 and
RXFP2 signaling can be explained by poor internalization and a lack
of β‐arrestin recruitment. AJP Cell Physiol. 2009;296:C1058‐C1066.
40. Cawston EE, Redmond WJ, Breen CM, Grimsey NL, Connor M, Glass
M. Real‐time characterization of cannabinoid receptor 1 (CB1) allos-
teric modulators reveals novel mechanism of action. Br J Pharmacol.
2013;170:893‐907.
41. Hossain MA, Bathgate RAD. Challenges in the design of insulin and
relaxin/insulin‐like peptide mimetics. Bioorg Med Chem. 2018;26:
2827‐2841.
42. Hossain MA, Kocan M, Yao ST, et al. A single‐chain derivative of the
relaxin hormone is a functionally selective agonist of the G protein‐
coupled receptor, RXFP1. Chem Sci. 2016;7:3805‐3819.
43. Bathgate RAD, Samuel CS, Burazin TCD, et al. Human relaxin gene
3 (H3) and the equivalent mouse relaxin (M3) gene: novel members
of the relaxin peptide family. J Biol Chem. 2002;277:1148‐1157.
44. Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ. Sere-
laxin‐mediated signal transduction in human vascular cells: bell‐
shaped concentration‐response curves reflect differential coupling to
G proteins. Br J Pharmacol. 2015;172:1005‐1019.
45. Halls ML, van der Westhuizen ET, Wade JD, Evans BA, Bathgate
RAD, Summers RJ. Relaxin family peptide receptor (RXFP1) coupling
to Gαi3 involves the C‐terminal Arg752 and localization within mem-
brane raft microdomains. Mol Pharmacol. 2009;75:415‐428.
46. Halls ML, Bathgate RAD, Summers RJ. Comparison of signaling path-
ways activated by the relaxin family peptide receptors, RXFP1 and
RXFP2, using reporter genes. J Pharmacol Exp Ther. 2007;320:281‐
290.
47. Ponsioen B, Zhao J, Riedl J, et al. Detecting cAMP‐induced Epac
activation by fluorescence resonance energy transfer: Epac as a
novel cAMP indicator. EMBO Rep. 2004;5:1176‐1180.
48. Matthiesen K, Nielsen J. Cyclic AMP control measured in two com-
partments in HEK293 cells: phosphodiesterase KM is more impor-
tant than phosphodiesterase localization. PLoS ONE. 2011;6:e24392.
49. Wachten S, Masada N, Ayling L-J, et al. Distinct pools of cAMP cen-
tre on different isoforms of adenylyl cyclase in pituitary‐derived
GH3B6 cells. J Cell Sci. 2010;123:95‐106.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
How to cite this article: Valkovic AL, Leckey MB, Whitehead
AR, et al. Real‐time examination of cAMP activity at relaxin
family peptide receptors using a BRET‐based biosensor.
Pharmacol Res Perspect. 2018;e00432. https://doi.org/
10.1002/prp2.432
VALKOVIC ET AL. | 15 of 15
